Oct 20, 2026
New York, United States, October 20, 2026 /MarketersMEDIA/ -- Protheragen, an ISO9001-certified preclinical contract research and analytical service provider, is emphasizing its integrated suite of services designed to help medical device manufacturers navigate rigorous regulatory pathways and bring safe, effective products to market. Its medical device analytical services span the full development lifecycle, addressing critical areas such as safety, biocompatibility, and performance validation.
The medical device industry faces increasing scrutiny from regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Protheragen supports global medical device firms by delivering end‑to‑end solutions throughout the full product development lifecycle, combining hands‑on testing expertise with deep regulatory knowledge.
Medical device safety testing is essential for reducing risk and preventing adverse patient events. Protheragen’s safety testing service includes bacterial endotoxin testing (BET) using state-of-the-art horseshoe crab lysates (LAL)) assays to quantify pyrogens, as well as sterility testing and bioburden testing to assess microbial contamination. These safety assessments are further complemented by antimicrobial efficacy testing, packaging integrity evaluations, and regulatory support to ensure devices meet stringent quality control requirements before approval.
In addition, Protheragen conducts thorough biocompatibility studies in accordance with ISO 10993 standards to evaluate how device materials interact with living tissues and biological systems. Its biological risk assessment covers a wide range of endpoints, including cytotoxicity, sensitization, irritation, systemic toxicity, genotoxicity, implantation effects, and hematological compatibility. By identifying potential local or systemic reactions—such as inflammation, toxicity, or allergic responses—these studies provide critical data for regulatory submissions and help confirm patient safety.
Beyond safety and biological evaluation, Protheragen also delivers rigorous validation and verification studies to confirm that medical devices consistently perform as intended and meet all design and manufacturing specifications. This service includes requirement analysis, usability and human factors testing, risk assessment, performance testing, and comprehensive documentation. Separately, process validation and verification services help ensure manufacturing consistency through protocol development, statistical analysis, critical process parameter control, and ongoing monitoring strategies. Additional support in risk management, quality management system (QMS) implementation, and regulatory compliance further strengthens Protheragen’s end-to-end medical device services.
Protheragen emphasizes that its integrated approach—combining medical device safety testing, biocompatibility studies, and validation & verification services—is designed to help clients mitigate risks, achieve regulatory compliance, and accelerate the delivery of safe medical devices to the global market.
About Protheragen
Protheragen is an ISO9001-certified supplier of preclinical contract research services and analytical services. Located in New York, the company provides comprehensive testing support to the pharmaceutical and medical device industries, with a focus on regulatory adherence, scientific rigor, and patient safety.
Contact Info:
Name: Hannah Green
Email: Send Email
Organization: Protheragen
Website: https://labs.protheragen.ai/
Release ID: 89206735
In the event of encountering any errors, concerns, or inconsistencies within the content shared in this press release, we kindly request that you immediately contact us at [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our dedicated team will be readily accessible to address your feedback within 8 hours and take appropriate measures to rectify any identified issues or facilitate press release takedowns. Ensuring accuracy and reliability are central to our commitment.
Boards change, projects change and even company names magically morph, but Dollar Bill asks whether it is real change or just the tired old format re-polished.
The National Australia Bank has announced it will axe up to 2500 jobs over this financial year, while also reducing the use of external consultants.
The network’s chief international anchor will sign off next year as CNN comes under controversial new ownership after the biggest media deal in history.
The activewear label is under new management, but has brought back some familiar faces – and is keen to set things right.
China is addicted to making cars, and it is dragging down the entire industry.
Kaiser Reef has repaid its Auramet gold loan, a move that boosts its monthly cash flow by about $600,000. The Henty gold mine in Tasmania fully funded the debt.
AI start-up Firmus’ planned public listing wasn’t derailed by its boss’ history. Will a retail chief’s alleged lies denying an affair scupper his shot at a float?
Accelerate Resources has unearthed near-60% manganese rock chips at its Woodie Woodie North project in WA, bolstering a 12km underexplored mineralised corridor.
Great Southern has hit high-grade gold in maiden RC drilling near Laverton in WA, with a top hit of 5m at 6.71g/t, including 3m at 10.4g/t, along a 4.7km corridor.
Barkly Rare Earths has expanded its NT rare earths discovery, with new drilling hitting significant intercepts up to 8km from previous results, including high-grade hits up to 4550ppm TREO.
The order comes after a long-running battle with an investment firm seeking back payment for the use of four planes by the airline.
The implosion in the share price of one neocloud company has highlighted just how vulnerable Wall Street is.
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.